Prognostic significance of AKT/mTOR signaling in advanced neuroendocrine tumors treated with somatostatin analogs

© 2012 Fernandes et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby...

ver descrição completa

Detalhes bibliográficos
Autor principal: Fernandes, Isabel (author)
Outros Autores: Pacheco, Teresa (author), Costa, Adília (author), Santos, Ana C. (author), Fernandes, Ana R. (author), Santos, Mara (author), Oliveira, António G. (author), Casimiro, Sandra (author), Quintela, António (author), Fernandes, Afonso (author), Ramos, Madalena (author), Costa, Luis (author)
Formato: article
Idioma:eng
Publicado em: 2022
Assuntos:
mTOR pathway
Neuroendocrine tumor
Somatostatin analogs
Texto completo:http://hdl.handle.net/10451/54617
País:Portugal
Oai:oai:repositorio.ul.pt:10451/54617

Texto Completo

http://hdl.handle.net/10451/54617

Registos relacionados